Literature DB >> 8757264

Expression of normal and mutant huntingtin in the developing brain.

P G Bhide1, M Day, E Sapp, C Schwarz, A Sheth, J Kim, A B Young, J Penney, J Golden, N Aronin, M DiFiglia.   

Abstract

Huntington's disease (HD) is caused by a genetic mutation that results in a polyglutamine expansion in huntingtin. The time course of neuronal loss in the HD striatum and other affected brain regions before the onset of symptoms is unknown. To determine the potential influence of huntingtin on brain development, we examined its expression in the developing mouse and in human control and HD brain. By Western blot, huntingtin was detected throughout the adult mouse brain and at all stages of embryonic and postnatal brain development. The protein increased significantly between postnatal day 7 (P7) and P15, which marks a period of active neuronal differentiation and enhanced sensitivity to excitotoxic injury in the rodent striatum. Immunoreactivity was found in neurons throughout the brain and localized mostly to the somatodendritic cytoplasm and to axons in fiber bundles. Staining was variable in different groups of neurons and within the same cell population. In developing brain, huntingtin was limited primarily to neuronal perikarya. Increased immunoreactivity in large neurons followed the gradient of neurogenesis and appeared in the basal forebrain and brainstem by embryonic days 15-17, in regions of cortex by P0-P1, and in the striatum by P7. In human brain at midgestation (19-21 weeks), huntingtin was detected in all regions. The brain of a 10-week-old infant with the expanded HD allele expressed a higher molecular weight mutant form of huntingtin at levels comparable to those of the wild-type protein. Thus, mutant huntingtin is expressed before neuronal maturation is complete. Results suggest that huntingtin has an important constitutive role in neurons during brain development, that heterogeneity in neuronal expression of the protein is developmentally regulated, and that the intraneuronal distribution of huntingtin increases in parallel with neuronal maturation. The presence of mutant huntingtin in the immature HD brain raises the possibility that neurons may be affected during brain development and possibly in the postnatal period when vulnerability to excitotoxic injury is at its peak.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757264      PMCID: PMC6578889     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

1.  Analysis of dynamin isoforms in mammalian brain: dynamin-1 expression is spatially and temporally regulated during postnatal development.

Authors:  K Faire; F Trent; J M Tepper; E M Bonder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

2.  Selective sparing of a class of striatal neurons in Huntington's disease.

Authors:  R J Ferrante; N W Kowall; M F Beal; E P Richardson; E D Bird; J B Martin
Journal:  Science       Date:  1985-11-01       Impact factor: 47.728

3.  p145, a major Grb2-binding protein in brain, is co-localized with dynamin in nerve terminals where it undergoes activity-dependent dephosphorylation.

Authors:  P S McPherson; K Takei; S L Schmid; P De Camilli
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

4.  Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity.

Authors:  C Ikonomidou; J L Mosinger; K S Salles; J Labruyere; J W Olney
Journal:  J Neurosci       Date:  1989-08       Impact factor: 6.167

Review 5.  Excitotoxic injury of the neostriatum: a model for Huntington's disease.

Authors:  M DiFiglia
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

6.  Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.

Authors:  R L Albin; A Reiner; K D Anderson; L S Dure; B Handelin; R Balfour; W O Whetsell; J B Penney; A B Young
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

7.  Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study.

Authors:  A Sotrel; R S Williams; W E Kaufmann; R H Myers
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

8.  Differential loss of striatal projection neurons in Huntington disease.

Authors:  A Reiner; R L Albin; K D Anderson; C J D'Amato; J B Penney; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

Authors:  J Nasir; S B Floresco; J R O'Kusky; V M Diewert; J M Richman; J Zeisler; A Borowski; J D Marth; A G Phillips; M R Hayden
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.

Authors:  J C Mazziotta; M E Phelps; J J Pahl; S C Huang; L R Baxter; W H Riege; J M Hoffman; D E Kuhl; A B Lanto; J A Wapenski
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

View more
  58 in total

1.  Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Authors:  A S Harris; E M Denovan-Wright; L C Hamilton; H A Robertson
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

4.  Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease.

Authors:  F R Fusco; Q Chen; W J Lamoreaux; G Figueredo-Cardenas; Y Jiao; J A Coffman; D J Surmeier; M G Honig; L R Carlock; A Reiner
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

5.  Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease.

Authors:  John P Miller; Jennifer Holcomb; Ismael Al-Ramahi; Maria de Haro; Juliette Gafni; Ningzhe Zhang; Eugene Kim; Mario Sanhueza; Cameron Torcassi; Seung Kwak; Juan Botas; Robert E Hughes; Lisa M Ellerby
Journal:  Neuron       Date:  2010-07-29       Impact factor: 17.173

6.  Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.

Authors:  Ahmad Khedraki; Eric J Reed; Shannon H Romer; Qingbo Wang; William Romine; Mark M Rich; Robert J Talmadge; Andrew A Voss
Journal:  J Neurosci       Date:  2017-07-19       Impact factor: 6.167

Review 7.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

Review 8.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

Review 9.  A role for autophagy in Huntington's disease.

Authors:  Katherine R Croce; Ai Yamamoto
Journal:  Neurobiol Dis       Date:  2018-08-24       Impact factor: 5.996

10.  Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Authors:  Liliana B Menalled; Jessica D Sison; Ying Wu; Melisa Olivieri; Xiao-Jiang Li; He Li; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.